Shield to develop new sales channels for Afecta
This article was originally published in Clinica
Shield Diagnostics says that it is in advanced discussion with a number of companies concerning the development of Shield's Afecta Activated Factor XII (AFT) cardiac diagnostic, with the intention of obtaining distribution through two more companies. Shield, which is already in partnership with Abbott Laboratories, is talking to companies that would run Afecta on point-of-care devices as well as those which would add it to a menu of tests on a laboratory analyser.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.